| Specificity |
The product is specific for Daratumumab. |
| Host Species |
Mouse |
| Immunogen |
Daratumumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| Competitive ELISA |
10-50 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG1 |
| Clonality |
Monoclonal |
| Clone ID |
9A6 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
ELISA binding of Anti-Daratumumab Antibody (9A6) (GenScript, A01998-40) with Daratumumab. While the antibody does not recognize the human IgG Fc fragment (data not shown).
Coating antigen: Daratumumab, 1 µg/ml.
Anti-Daratumumab Antibody (9A6) (GenScript, A01998-40) dilutions start from 1,000 ng/ml.
EC50= 43.43 ng/ml.
Anti-Daratumumab Antibody (9A6) (GenScript, A01998-40) blocks Daratumumab binding with Human CD38 recombinant protein.
Coating antigen: CD38 0.5 µg/ml.
Daratumumab final concentration: 60 ng/ml.
Anti-Daratumumab antibody dilutions start from 30 μg/ml.
IC50= 0.1178 μg/ml.
| Target Background |
Daratumumab (Darzalex) is a human monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma. Daratumumab binds to CD38 on multiple myeloma cells and induces cells to apoptose via antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity.GenScript Anti-Daratumumab Antibody (9A6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Daratumumab. |
| Synonyms |
Mouse monoclonal antibody to Darzalex |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
